TABLE 3.
Effect of application of BMP-9 or LDN193189/BMP-9 to the apical chamber on the apical-to-basolateral and the basolateral-to-apical permeability of currently marketed statins across human endothelial cell monolayers
| Atorvastatin | Pravastatin | Rosuvastatin | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Papp (A–B) (cm/s) × 10−6 | Papp (B–A) (cm/s) × 10−6 | Influx Ratio | Papp (A–B) (cm/s) × 10−6 | Papp (B–A) (cm/s) × 10−6 | Influx Ratio | Papp (A–B) (cm/s) × 10−6 | Papp (B–A) (cm/s) × 10−6 | Influx Ratio | |
| Control | 19.69 ± 7.02 (95% CI: 11.75, 27.63) | 5.50 ± 2.99 (95% CI: 2.12, 8.88) | 3.58 | 11.87 ± 5.41 (95% CI: 5.75, 17.99) | 2.52 ± 1.43 (95% CI: 0.90, 4.14) | 4.71 | 17.27 ± 4.02 (95% CI: 12.72, 21.82) | 6.34 ± 3.05 (95% CI: 2.89, 9.79) | 2.72 |
| DMSO (vehicle) | 19.00 ± 7.21 (95% CI: 10.84, 27.16) | 5.63 ± 3.45 (95% CI: 1.73, 9.53) | 3.37 | 11.76 ± 4.55 (95% CI: 6.61, 16.91) | 2.71 ± 2.00 (95% CI: 0.45, 4.97) | 4.34 | 16.87 ± 5.00 (95% CI: 11.21, 22.53) | 6.04 ± 1.71 (95% CI: 4.10, 7.98) | 2.79 |
| BMP-9 (1 nM) | 36.62 ± 8.50 (95% CI: 27.00, 46.24) | 4.91 ± 1.99 (95% CI: 1.85, 7.16) | 7.45 | 25.81 ± 5.41 (95% CI: 19.69, 31.93) | 2.00 ± 0.88 (95% CI: 1.00, 3.00) | 12.91 | 34.69 ± 6.00 (95% CI: 27.90, 41.48) | 5.20 ± 1.68 (95% CI: 3.30, 7.10) | 6.67 |
| BMP-9 (1 nM) + LDN193189 (10 nM) | 20.65 ± 8.51 (95% CI: 11.02, 30.28) | 5.61 ± 2.00 (95% CI: 3.35, 7.87) | 3.68 | 12.17 ± 4.23 (95% CI: 7.38, 16.96) | 2.92 ± 1.12 (95% CI: 1.65, 4.19) | 4.17 | 17.86 ± 5.22 (95% CI: 11.95, 23.77) | 6.49 ± 1.57 (95% CI: 4.71, 8.27) | 2.75 |
CI, confidence interval.